Novel Drugs and Devices to Lower Intraocular Pressure: Revolutionary Advances Poised to Grow at a Rapid Rate
Mohali, India, September 12, 2016 --(PR.com)-- Roots Analysis has announced the addition of the “Novel Drugs and Devices to Lower Intraocular Pressure, 2016 - 2026” report to its list of offerings. The report provides a detailed study on the current market landscape, future trends and applications of these novel treatment options. It also provides a detailed perspective on how the market is likely to evolve over the next ten years.
Harpreet Singh, the principle analyst, said, “Extensive research and an improved understanding of the complex pathways involved in aqueous humor dynamics have led to the development of a number of novel drugs and devices for lowering elevated intraocular pressure (IOP). Primarily developed to overcome the drawbacks of existing treatment modalities, a number of these novel treatment methods have already been shown to be capable of treating ocular hypertension related disorders in a better and more efficient manner.”
Among other things, the report includes the following:
A detailed analysis of the current market landscape of novel drugs and devices, including an overview of the key players involved, the status of development of various pipeline candidates and target patient segments.
Comprehensive drug profiles covering mechanisms of action, clinical trial details and recent developments.
Comprehensive device profiles highlighting the IOP reduction approach employed by each novel device, key performance drivers, and safety and efficacy data (wherever available) of novel surgical devices that have either been approved or are in the advanced stages of clinical development.
A comparative analysis of minimally-invasive glaucoma surgery (MIGS) devices based on various parameters, such as drainage route, length of the implant, involvement of the conjunctiva in the device placement process, type of procedure (ab interno or ab externo), duration of the procedure and ability of the device to treat 360 degrees.
Informed projections on the likely future evolution of these novel drugs, sustained release drug delivery devices and surgical devices over the next decade.
Singh further stated, “With the aging world population, the prevalence of ocular hypertension related disorders is likely to increase in the coming future. Accordingly, the market for novel pharmacological interventions aimed to ameliorate such conditions is likely to grow at an annualized rate of 83.9%. Similarly, significant growth is also expected in the sustained release drug delivery devices and novel surgical devices segment in the foreseen future.”
The report is likely to benefit big and small pharma companies involved in the development of drugs and devices to treat elevated IOP. In particular, you could benefit if you are an:
Investor
CXO level decision maker
R&D Manager
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
Strategy Manager
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/novel-drugs-and-devices-to-lower-intraocular-pressure-2016-2026/138.html
or email sales@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
Harpreet Singh, the principle analyst, said, “Extensive research and an improved understanding of the complex pathways involved in aqueous humor dynamics have led to the development of a number of novel drugs and devices for lowering elevated intraocular pressure (IOP). Primarily developed to overcome the drawbacks of existing treatment modalities, a number of these novel treatment methods have already been shown to be capable of treating ocular hypertension related disorders in a better and more efficient manner.”
Among other things, the report includes the following:
A detailed analysis of the current market landscape of novel drugs and devices, including an overview of the key players involved, the status of development of various pipeline candidates and target patient segments.
Comprehensive drug profiles covering mechanisms of action, clinical trial details and recent developments.
Comprehensive device profiles highlighting the IOP reduction approach employed by each novel device, key performance drivers, and safety and efficacy data (wherever available) of novel surgical devices that have either been approved or are in the advanced stages of clinical development.
A comparative analysis of minimally-invasive glaucoma surgery (MIGS) devices based on various parameters, such as drainage route, length of the implant, involvement of the conjunctiva in the device placement process, type of procedure (ab interno or ab externo), duration of the procedure and ability of the device to treat 360 degrees.
Informed projections on the likely future evolution of these novel drugs, sustained release drug delivery devices and surgical devices over the next decade.
Singh further stated, “With the aging world population, the prevalence of ocular hypertension related disorders is likely to increase in the coming future. Accordingly, the market for novel pharmacological interventions aimed to ameliorate such conditions is likely to grow at an annualized rate of 83.9%. Similarly, significant growth is also expected in the sustained release drug delivery devices and novel surgical devices segment in the foreseen future.”
The report is likely to benefit big and small pharma companies involved in the development of drugs and devices to treat elevated IOP. In particular, you could benefit if you are an:
Investor
CXO level decision maker
R&D Manager
Business Intelligence / Scientific Analyst
Licensing / Portfolio Manager
Strategy Manager
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/novel-drugs-and-devices-to-lower-intraocular-pressure-2016-2026/138.html
or email sales@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at info@rootsanalysis.com
Contact
Roots Analysis
Gaurav Chaudhary
+1-604-595-4954
www.rootsanalysis.com
Gaurav Chaudhary
+1-604-595-4954
www.rootsanalysis.com
Contact
Categories